Fig. 3

TINCR enhances the resistance to oxaliplatin in HCC cells. A, The survival percentage of HepG2 and HuH7 cells transfected with si-TINCRs or scrambled control, treated with increasing concentration of oxaliplatin (OXA). B-D, Representative images of apoptosis assay of increasing concentration in HepG2 cells transfected with si-TINCRs or scrambled control (B), and quantification in HuH7 (C) and HepG2 (D) cells. E, The survival percentage of HepG2 and HuH7cells transfected with pcDNA3.1-TINCR or empty vector, treated with increasing concentration of OXA. F-H, Representative images apoptosis assays of increasing concentration of OXA in HepG2 cells transfected with pcDNA3.1-TINCR or empty vector (F), and quantification in HuH7 (G) and HepG2 (H) cells. Data are expressed as the mean ± SD of at least three independently repeated experiments. *P < 0.05; **P < 0.01; ***P < 0.001; NS: no significance